Littérature scientifique sur le sujet « Lipoprotéines de haute densité – Emploi en thérapeutique »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Lipoprotéines de haute densité – Emploi en thérapeutique ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Lipoprotéines de haute densité – Emploi en thérapeutique"
SAIDI, Yassamine R., et Amel DOUMANDJI. « Anticholesterolemic activity of Moringa oleifera leaves methanolic extract in Triton X-100 induced hypercholesterolemic mice ». Nutrition & ; Santé 12, no 01 (30 juin 2023) : 31–37. http://dx.doi.org/10.30952/ns.12.1.4.
Texte intégralBaillie, G. Mark, Jeffrey T. Sherer et C. Wayne Weart. « Insulin and Coronary Artery Disease : Is Syndrome X the Unifying Hypothesis ? » Annals of Pharmacotherapy 32, no 2 (février 1998) : 233–47. http://dx.doi.org/10.1345/aph.13398.
Texte intégralThèses sur le sujet "Lipoprotéines de haute densité – Emploi en thérapeutique"
Begue, Floran. « Lipoprotéines de haute densité (HDL). Implications diagnostiques et thérapeutiques au cours de la COVID 19 ». Electronic Thesis or Diss., La Réunion, 2024. http://www.theses.fr/2024LARE0002.
Texte intégralHigh-density lipoproteins (HDL) are crucial for maintaining good cardiovascular health due to their ability to transport cholesterol from peripheral tissues to the liver for elimination via a "reverse transport of cholesterol” mechanism. Moreover, HDL exhibits several other advantageous properties, including anti-inflammatory, antioxidant, and anti-infectious activities. In inflammatory situations, such as those encountered during viral infections, HDL can undergo both quantitative alterations, with a drop in circulating concentration, and qualitative alterations, such as a change in composition and loss of protective activities. Humanity is still struggling with coronavirus disease (COVID-19), characterized by acute inflammation and responsible for over 6.9 million deaths worldwide to date. The aim of my thesis was to characterize the quantitative and qualitative changes in HDL during COVID-19, to identify specific biomarkers of the changes found in HDL, and to conduct a therapeutic trial of HDL mimetic supplementation during this disease. Quantification of circulating lipoproteins in the plasma of patients with severe COVID 19 shows a significant decrease in HDL and other lipoproteins, which may be predictive biomarkers of disease severity. Analysis of lipoprotein distribution shows a pro-atherogenic profile, with the presence of small, dense low-density lipoproteins (LDL) in the plasmas of patients with severe COVID-19. Qualitative mass spectrometry analysis of the composition of both HDL and LDL showed an increased presence of proteins from the acute phase of inflammation, to the detriment of the apoprotein part of these lipoproteins when isolated from the plasma of COVID-19 patients. When tested on human endothelial cells from primary culture, HDL demonstrated a significant alteration in their anti-apoptotic and anti-inflammatory properties when purified from the plasma of COVID-19 patients. Finally, the anti-inflammatory properties of recombinant HDL injections were demonstrated in a patient admitted to intensive care with a severe form of COVID-19. In conclusion, my thesis work provides some new insights into lipoprotein modifications during infectious disease, in this case COVID-19. It also opens up promising prospects for research into the use of HDL both as a biomarker of inflammatory disease severity and as a means of therapeutic control
Malaval, Camille. « Régulation de la captation hépatique des HDL : la voie F1-ATPase/P2Y13 : de la caractérisation cellulaire au modèle animal ». Toulouse 3, 2008. http://thesesups.ups-tlse.fr/390/.
Texte intégralHDL mediate the elimination of cholesterol thanks to their internalization by hepatocytes. We identified in hepatocytes a new pathway for HDL endocytosis as following: stimulation of an ectopic cell surface F1-ATPase by the HDL apolipoprotein A-I, induces the production of ADP which in turn activates the purinergic receptor P2Y13, triggering HDL endocytosis through unknown low affinity receptor(s). In one hand, we identified a major role of the small GTPase RhoA and its effector ROCK1 downstream P2Y13. This cell signalling stimulates the HDL endocytosis by remodelling actin cytoskeleton. In other hand, the study in mice showed the crucial role of P2Y13 in HDL catabolism and in the subsequent cholesterol biliary elimination. Taking together, these results demonstrate the importance of the receptor P2Y13 in cholesterol metabolism. Thus, P2Y13 appears as a new pharmacological target to control reverse cholesterol transport and prevent hypercholesterolemia
Cardelain, Xavier. « Etude "in vivo" et "in vitro" des propriétés antioxydantes du probucol vis à vis des lipoprotéines de basse densité (L. D. L. ) ». Paris 5, 1993. http://www.theses.fr/1993PA05P207.
Texte intégralBadiou, Stéphanie. « Dyslipidémie chez le sujet infecté par le virus de l'immuno-déficience humaine : caractérisation, influence des traitements antirétroviraux et approche thérapeutique ». Montpellier 1, 2003. http://www.theses.fr/2003MON13512.
Texte intégralParmentier, Stéphane. « Le b-carotène : son rôle dans la prévention de l'oxydation des lipoprotéines de basse densité (L.D.L.) : études "in vitro" et "ex vivo" ». Paris 5, 1995. http://www.theses.fr/1995PA05P113.
Texte intégralDo, Hong Quang. « Régulation du cholestérol HDL : approche génétique et nutritionnelle : intérêt de stérols d'origine marine ». Nantes, 2008. https://archive.bu.univ-nantes.fr/pollux/show/show?id=bfff3c8b-f4f0-40af-8c8d-4a9ea70c3bb1.
Texte intégralEpidemiologic and experimental studies showed that genetic polymorphisms (non modifiable factors) and lifestyle (modifiable factors) could modulate the concentrations of cholesterol, HDL-C and then the individual susceptibility to atherosclerosis, the major cause of death in the developed countries. In our studies, we evaluated 1) the potential associations between the genetic polymorphisms (APOAI, APOE, CETP, PPARA) and the concentrations of HDL-C in 857 individuals free of cardiovascular disease from the PRIME prospective cohort study and 2) the in vitro influence of sterols extracted from sponge (Ciocallypta sp. ) on the intestinal absorption of cholesterol. In the PRIME study, we found significant associations between the polymorphism CETP A373P and the concentrations of HDL-C, ApoAI, LpAI and LpAIAII. In fact, the rare allele c was less frequent in the high-HDL-C group. The association disappeared when adjusted for triglycerides. Another positive association has been found between allele 2 of apo E and ApoAI and LpAI. The other polymorphisms are absent in the cohort or have no effect on HDL-C. In the study of the influence of sponge sterols on intestinal absorption of cholesterol, we found that the 24-isopropylcholesterol reduces the absorption of cholesterol and increase the expression of ABCA-1, the carrier playing a major role in cholesterol efflux and in HDL biogenesis. The results highlight the importance of different factors in HDL level determination and in intestinal absorption of cholesterol
Tanaka, Sébastien. « Évaluation fonctionnelle et structurale des HDL plasmatiques au cours des états inflammatoires ». Thesis, La Réunion, 2019. http://www.theses.fr/2019LARE0032.
Texte intégralContext: the main function of HDLs is the reverse transport of cholesterol from the tissues back to the liver, thus conferring a cardiovascular protective role. HDL also DISPLAY other endothelioprotective properties, in particular anti-inflammatory, antioxidant, anti-apoptotic, anti-infectious and antithrombotic effects. During certain states of chronic inflammation, such as atherosclerosis, changes in HDL function and structure have been previously described, which can have negative consequences on morbidity and mortality. The objective of this thesis was to investigate the structural and concentration changes occurring in human sepsis a model of exacerbated acute inflammation. In addition, we tested the effects of injecting human reconstituted HDLs in several experimental sepsis models. Results: first part, by comparing two exacerbated inflammatory conditions, we showed that the plasma HDL concentration was drastically decreased in patients at the acute phase of sepsis while it was not modified in polytrauma patients. A second part focused on comparing patients in septic shock and non-septic ICU patients. We confirmed these differences in HDL concentration. In addition, septic patients had more large HDL particles compared to control patients who had more small functional particles. A kinetic study of HDL concentration in 205 septic ICU patients showed a drastic decrease at the acute phase and then an increase at patient's recovery without returning to the basal concentrations observed before the hospitalization. HDL concentration was associated with certain morbidity criteria (SOFA score, days alive without mechanical ventilation), but no link to mortality was found in this work. A proteomic analysis of plasma from septic patients found a drastic decrease in many apolipoproteins compared to plasma from non-septic patients. Finally, the injection of human reconstituted HDLs in three mouse models of sepsis showed a decrease in mortality, as well as a decrease in many markers of inflammation and bacterial concentrations in both plasma and tissues. Conclusion: during sepsis, there are both quantitative and qualitative modifications of HDLs with a significant decrease in their concentrations, but also increased particle size and changes in the composition of these particles. The quantitative aspect alone does not seem sufficient to predict patient outcomes; evaluation of HDL dysfunction could represent a better biomarker. In addition, injection of functional HDL has proven its effectiveness in several mouce models. Further studies to characterize these dysfunctions are needed before completing a randomized trial evaluating therapeutic injection of HDL during sepsis in patients
Materne, Clément. « Risque résiduel et mortalité précoce post-infarctus du myocarde : fonctionnalité des HDL, nouvelle promesse thérapeutique ». Electronic Thesis or Diss., Sorbonne université, 2023. https://accesdistant.sorbonne-universite.fr/login?url=https://theses-intra.sorbonne-universite.fr/2023SORUS545.pdf.
Texte intégralFor more than 50 years, a low HDL-C level has been recognized as an independent risk factor for cardiovascular disease. More recently, epidemiological studies have demonstrated that extremely high HDL-C concentrations are also associated with increased cardiovascular mortality, reflecting a U-shaped relationship between mortality and circulating HDL-C concentrations. In addition, failure of therapeutic trials designed to increase HDL-C have raised the concept of quality versus quantity, meaning that the physiological role of HDL particles is more important than their circulating concentration. My research work was dedicated to further understand molecular mechanisms controlling HDL biological functions that contribute to residual risk in individuals in secondary prevention. I demonstrated that the combination of two biomarkers known to be associated with early death after myocardial infarction, namely HDL cholesterol efflux capacity (CEC) and plasma interleukin-1ß concentration (IL-1ß), allows a better identification of patients at higher risk of recurrent cardiovascular events in the year following myocardial infarction. Thus, an impaired cholesterol efflux capacity together with an elevated IL-1ß concentration increase the risk of a second clinical event by 3. I demonstrated that HDL particles of patients at high risk are also dysfunctional in their ability to limit the activation of endothelial cells, promoting adhesion and monocyte recruitment. Finally, HDL particles from these patients promote the activation of the NLRP3 inflammasome in macrophages and subsequent IL-1ß secretion. Our results show that patients with altered biological properties of HDL particles combined with elevated systemic inflammation have an increased risk of early death after myocardial infarction. We thus propose a new method for patient stratification, allowing a better identification of patients at higher cardiovascular risk eligible for personalized medical care